EyePoint, Inc. Cash Flow Statement
EYPT / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
EyePoint, Inc. used $240M in operating cash flow and negative free cash flow of $243M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$232.0M | -$130.9M | -$70.8M | -$102.3M | -$58.4M | -$56.8M | -$18.5M | -$53.2M | -$18.5M | -$21.5M | $6.3M | -$13.4M | -$11.9M | $8.8M | -$8.6M |
| Depreciation & Amortization | $2.3M | $1.5M | $464.0K | - | $311.0K | $144.0K | $91.0K | - | - | $152.0K | $112.0K | $139.0K | $225.0K | $37.0K | $53.0K |
| Operating Cash Flow | -$240.1M | -$126.2M | $1.9M | -$65.0M | -$50.1M | -$56.7M | -$20.5M | -$21.9M | -$20.5M | -$16.3M | $10.3M | -$10.7M | -$8.7M | $9.9M | -$3.2M |
| Capital Expenditures | $3.3M | $4.1M | $3.5M | $2.1M | $156.0K | $213.0K | $147.0K | $108.0K | $147.0K | $113.0K | $161.0K | $248.0K | $68.0K | $15.0K | $133.0K |
| Free Cash Flow | -$243.4M | -$130.3M | -$1.6M | -$67.2M | -$50.3M | -$56.9M | -$20.6M | -$22.0M | -$20.6M | -$16.4M | $10.1M | -$10.9M | -$8.8M | $9.9M | -$3.3M |
| FCF Margin | -775.8% | -301.1% | -3.5% | -162.2% | -136.0% | -279.5% | -273.7% | -743.5% | -3497.8% | -1014.1% | 38.2% | -314.4% | -411.3% | 42.9% | - |